This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

Relationship: 335

Title

A descriptive phrase which clearly defines the two KEs being considered and the sequential relationship between them (i.e., which is upstream, and which is downstream). More help

Inhibition, VegfR2 leads to Reduction, Angiogenesis

Upstream event
The causing Key Event (KE) in a Key Event Relationship (KER). More help
Downstream event
The responding Key Event (KE) in a Key Event Relationship (KER). More help

Key Event Relationship Overview

The utility of AOPs for regulatory application is defined, to a large extent, by the confidence and precision with which they facilitate extrapolation of data measured at low levels of biological organisation to predicted outcomes at higher levels of organisation and the extent to which they can link biological effect measurements to their specific causes.Within the AOP framework, the predictive relationships that facilitate extrapolation are represented by the KERs. Consequently, the overall WoE for an AOP is a reflection in part, of the level of confidence in the underlying series of KERs it encompasses. Therefore, describing the KERs in an AOP involves assembling and organising the types of information and evidence that defines the scientific basis for inferring the probable change in, or state of, a downstream KE from the known or measured state of an upstream KE. More help

AOPs Referencing Relationship

AOP Name Adjacency Weight of Evidence Quantitative Understanding Point of Contact Author Status OECD Status
Disruption of VEGFR Signaling Leading to Developmental Defects adjacent High High Cataia Ives (send email) Open for citation & comment EAGMST Under Review

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) that help to define the biological applicability domain of the KER.In general, this will be dictated by the more restrictive of the two KEs being linked together by the KER.  More help

Sex Applicability

An indication of the the relevant sex for this KER. More help

Life Stage Applicability

An indication of the the relevant life stage(s) for this KER.  More help

Key Event Relationship Description

Provides a concise overview of the information given below as well as addressing details that aren’t inherent in the description of the KEs themselves. More help

VEGF signals promote endothelial cell motility, filopodial extension and proliferation, and together with Notch signaling controls whether specific endothelial cells (ECs) become pioneering ‘EC-tip’ cells (non-proliferating) or trailing ‘EC-stalk’ cells (proliferating). VEGFR2 activation is the master switch that promotes motility and exploratory behaviors of leading EC-tip cells and a mitogenic effect on trailing EC-stalk cells [EIlken and Adams, 2010; Herbert and Stanier 2011; Blanco and Gerhardt, 2013]. An early step is EC-tip cell selection [Eilken and Adams, 2010]. Endothelial cells are normally suppressed in their tip cell behaviors by Notch-Delta signaling [Blanco and Gerhardt, 2013; Li et al. 2014]. This lateral inhibition is broken when VEGFR2 is activated by VEGF-A.  Delta-like 4 (Dll4), a membrane-bound ligand for Notch1 and Notch4, is selectively expressed in response to VEGF-A induction. This down-regulates VEGFR-2 expression in prospective EC-stalk cells but promotes VEGFR2 expression in EC-tip cells, enabling them to extend filopodial processes along VEGF-A rich paths thus orienting the angiogenic sprout [Williams et al. 2006]. VEGF-A rich corridors are established during in vivo development by local VEGFA gradients and the distribution of soluble VEGFR-1, a so-called ‘decoy receptor’ sequestered and released during enzymatic remodeling of ECM, both serving to channel sprouting progression along VEGFA-rich corridors [Roberts et al. 2004; Chappell et al. 2009 and 2016].

Evidence Collection Strategy

Include a description of the approach for identification and assembly of the evidence base for the KER. For evidence identification, include, for example, a description of the sources and dates of information consulted including expert knowledge, databases searched and associated search terms/strings.  Include also a description of study screening criteria and methodology, study quality assessment considerations, the data extraction strategy and links to any repositories/databases of relevant references.Tabular summaries and links to relevant supporting documentation are encouraged, wherever possible. More help

Evidence Map 2.0

ID Experimental Design Species Upstream Observation Downstream Observation Citation (first author, year) Notes

Evidence Map

Addresses the scientific evidence supporting KERs in an AOP setting the stage for overall assessment of the AOP. More help
Title First Author
Biological Plausibility
Dose Concordance
Temporal Concordance
Incidence Concordance
Biological Plausibility
Dose Concordance Evidence
Temporal Concordance Evidence
Incidence Concordance Evidence
Uncertainties and Inconsistencies
Addresses inconsistencies or uncertainties in the relationship including the identification of experimental details that may explain apparent deviations from the expected patterns of concordance. More help

Many physiological states influence VEGF-A production (e.g., hypoxia, estrogen) and post-VEGFR2 signaling. For example, VEGFR2 signals may be influenced by crosstalk with VEGFR1 and VEGFR3, other receptor tyrosine kinases (FGFR, EGFR), G-protein coupled receptors (CXCRs and CCRs), and GPI-linked surface receptors (uPAR) [Kleinstreuer et al. 2011]. The ToxCast pVDC signature includes assays for many of these targets and shows that environmental chemicals perturbing VEGFR2 also affect molecular targets in other signaling system [Knudsen et al. 2016]. Crosstalk between VEGFR-2 and other pro-angiogenic receptor tyrosine kinase (RTK) activities such as PDGFR or FGFR is known. This crosstalk has been embraced in the search for clinically efficacious synergistic kinase anti-angiogenesis strategies in suppressing tumorigenic growth [Lin et al. 2018] but is an uncertainty for establishing a role for KER:335 in the disruption of blood vessel morphogenesis (KE:28). For example, the fungal metabolite Epoxyquinol B inhibits kinase activity across several RTKs including VEGFR and PDGFR and blocks VEGF-induced migration and tubulogenesis in human umbilical vein endothelial cells (HUVECs) [Kamiyama et al. 2008]. Anlotinib inhibits cell migration and microvessel formation in the rat aortic ring assay and chicken chorioallantoic membrane assay via the ERK signaling pathway in both species [Lin et al. 2018]. Derazantinib at 0.1 µM to 3 µM blocked intersegmental vessel (ISV) migration linked to VEGF, PDGF, or FGF pathways in zebrafish embryos [Kotini et al. 2020].

Still other pathways may be relevant with regards to developmental angiogenesis. For example, the endothelial TIE2 receptor is essential for ISV outgrowth in zebrafish embryos [Li et al. 2014] and TGFβ1 signaling in the formation of tubular networks in human vascular endothelial cells (HUVECs) [Zhang et al. 2021]. VEGF-dependent cell migration in HUVECs is also facilitated by the urokinase-type plasminogen activator receptor (uPAR), a system linked to cell-ECM interactions and Notch components: Notch1 receptor and ligands (Dll1, Dll4, Jag1) in endothelial cells on one hand, and uPA, uPAR, TGFβ1, integrin β3, Jag1, Notch3 receptor in mural cells on the other hand [Beloglazova et al. 2021]. Both an increase on pro-angiogenic factors as well as a decrease in anti-angiogenic factors (Notch signaling) can have similar outcomes. Crosstalk in these heterogeneous systems point to cell-specific patterns of gene expression as a critical determinant of RTK expression and cell-type specificity. As such, quantitative linkages to VEGF signaling must consider the uncertainties from effects to other MIEs.

Known modulating factors

This table captures specific information on the MF, its properties, how it affects the KER and respective references.1.) What is the modulating factor? Name the factor for which solid evidence exists that it influences this KER. Examples: age, sex, genotype, diet 2.) Details of this modulating factor. Specify which features of this MF are relevant for this KER. Examples: a specific age range or a specific biological age (defined by...); a specific gene mutation or variant, a specific nutrient (deficit or surplus); a sex-specific homone; a certain threshold value (e.g. serum levels of a chemical above...) 3.) Description of how this modulating factor affects this KER. Describe the provable modification of the KER (also quantitatively, if known). Examples: increase or decrease of the magnitude of effect (by a factor of...); change of the time-course of the effect (onset delay by...); alteration of the probability of the effect; increase or decrease of the sensitivity of the downstream effect (by a factor of...) 4.) Provision of supporting scientific evidence for an effect of this MF on this KER. Give a list of references.  More help

Domain of Applicability

A free-text section of the KER description that the developers can use to explain their rationale for the taxonomic, life stage, or sex applicability structured terms. More help

Domain of Applicability: The de novo assembly of endothelial cells into the primitive capillary network in an early embryo (vasculogenesis) or a tubular network in vitro (tubulogenesis) are both driven by VEGF-A signaling. A critical effect on developmental angiogenesis aligns with the Gene Ontology (GO) term ‘negative regulation of blood vessel morphogenesis’ (GO:0016525), defined as “Any process that stops, prevents, or reduces the frequency, rate or extent of angiogenesis”. Differences exist among the 110 genes mapped to this annotation in the Mouse Gene Ontology Browser (http://www.informatics.jax.org/vocab/gene_ontology/, last accessed November 30, 2021). Although the genetic signals and responses may differ between vasculogenesis and angiogenesis [Drake et al. 2007; Knudsen and Kleinstreuer, 2011], disruption of the former process ultimately leads to a reduction in the latter during development and so both are in the DoA for this KER.